Revance Therapeutics (NASDAQ:RVNC) Stock Price Up 7%

Revance Therapeutics Inc (NASDAQ:RVNC) shares rose 7% on Thursday . The stock traded as high as $13.28 and last traded at $13.08, approximately 608,031 shares traded hands during trading. An increase of 41% from the average daily volume of 430,750 shares. The stock had previously closed at $12.22.

RVNC has been the topic of several research reports. Zacks Investment Research upgraded shares of Revance Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday. Mizuho reiterated a “buy” rating and set a $37.00 price objective on shares of Revance Therapeutics in a research note on Wednesday, April 24th. ValuEngine upgraded shares of Revance Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. William Blair reiterated an “outperform” rating on shares of Revance Therapeutics in a research note on Tuesday. Finally, Barclays initiated coverage on shares of Revance Therapeutics in a research note on Tuesday, June 11th. They set an “overweight” rating and a $28.00 price objective on the stock. Five analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Revance Therapeutics currently has an average rating of “Buy” and an average price target of $33.09.

The company’s 50 day moving average is $12.39. The stock has a market cap of $537.76 million, a P/E ratio of -3.19 and a beta of 1.00. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.13 and a current ratio of 5.59.

Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.86) EPS for the quarter, meeting the consensus estimate of ($0.86). Revance Therapeutics had a negative net margin of 3,745.97% and a negative return on equity of 79.28%. As a group, analysts expect that Revance Therapeutics Inc will post -3.68 EPS for the current fiscal year.

Several large investors have recently made changes to their positions in RVNC. Dimensional Fund Advisors LP boosted its position in shares of Revance Therapeutics by 197.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 225,708 shares of the biopharmaceutical company’s stock worth $4,543,000 after buying an additional 149,952 shares during the period. Geode Capital Management LLC boosted its position in shares of Revance Therapeutics by 14.3% during the fourth quarter. Geode Capital Management LLC now owns 385,818 shares of the biopharmaceutical company’s stock worth $7,766,000 after buying an additional 48,325 shares during the period. Metropolitan Life Insurance Co. NY boosted its position in shares of Revance Therapeutics by 371.2% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 10,875 shares of the biopharmaceutical company’s stock worth $219,000 after buying an additional 8,567 shares during the period. Jane Street Group LLC purchased a new position in shares of Revance Therapeutics during the fourth quarter worth $274,000. Finally, Legal & General Group Plc boosted its position in shares of Revance Therapeutics by 21.7% during the fourth quarter. Legal & General Group Plc now owns 6,445 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 1,150 shares during the period. Institutional investors own 94.81% of the company’s stock.

About Revance Therapeutics (NASDAQ:RVNC)

Revance Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which is in phase III clinical trials to treat glabellar (frown) lines and cervical dystonia; and in phase II clinical trials for the treatment of plantar fasciitis, adult upper limb spasticity, and chronic migraine.

Featured Article: Green Investing

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.